Furthermore, an antibody–drug conjugate of PTGFRN conjugated with saporin has been shown to be effective against PTGFRN-positive cancer cells, such as epidermoid carcinoma, spindle carcinoma, and medulloblastoma [35, 36]. Here, PTGFRN is linked to squamous cell carcinoma.